Kisspeptin

Plain-English version: kisspeptin is a small protein (a "peptide") that your own body produces in the brain. Think of your reproductive hormones as a factory production line. Kisspeptin is the foreman who gives the very first order — everything downstream (the release of GnRH, then LH and FSH from the pituitary, then testosterone or estrogen from the gonads) only happens after kisspeptin says "go."

The peptide is made from the KISS1 gene as a 145-amino-acid precursor that the body trims into shorter active pieces. The main forms you will see named are kisspeptin-54 (the full-length form used in most clinical trials) and kisspeptin-10 (a shorter fragment). All the active forms end in the same 10-amino-acid tail that is the part the receptor actually recognizes, which is why they share the same core action but differ in how long they last in the body.

A quirky origin story worth knowing: kisspeptin was first discovered as "metastin," a molecule that suppressed cancer spread, and it was named after Hershey's Kisses (the research was done in Hershey, Pennsylvania). Its central role in reproduction was only uncovered in 2003, when two groups found that people and mice born with a broken kisspeptin receptor (GPR54, also called KISS1R) never went through puberty and had a form of infertility called hypogonadotropic hypogonadism — low sex hormones caused by a missing signal from the brain rather than a broken gonad.^[1] That single human genetic finding is the strongest possible proof that kisspeptin is essential: remove the ability to hear its signal, and the entire reproductive system fails to start.

The credibility caveat, up front: kisspeptin being a natural, well-understood signal does not make it an approved medicine. It is not FDA-approved for any indication. In the United States it is investigational — available only through research and clinical-trial protocols, or as an unregulated research-grade powder. Its status in pharmacy compounding remains unsettled and it should not be assumed to be legally available for therapeutic use. For the broader legal picture, see Are Peptides Legal?

Takeaway first: kisspeptin works by switching on the neurons that control your reproductive hormones. It does not act on the testes or ovaries directly — it acts at the very top of the chain, in the brain, which is why its effects ripple all the way down to testosterone, estrogen, and ovulation. It also lights up emotional and sexual circuits in the brain, separately from its hormone effects.

1. The hormone cascade (the core mechanism)

The reproductive system is often called the HPG axis — hypothalamus, pituitary, gonads. Kisspeptin sits just above it and drives it in a strict order:

• Kisspeptin → GnRH: kisspeptin binds the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus and makes them fire, releasing gonadotropin-releasing hormone.
• GnRH → LH and FSH: GnRH travels to the pituitary gland and triggers release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
• LH/FSH → testosterone / estrogen and eggs: those gonadotropins act on the testes (testosterone, sperm) or ovaries (estrogen, egg maturation, ovulation).

The human proof that this hierarchy is real, and that kisspeptin sits at the top of it, is the 2003 genetics work: knock out the receptor and the whole chain never activates.^[1] When researchers later gave kisspeptin-54 to healthy men by infusion, LH, FSH, and testosterone all rose significantly compared with a saline (placebo) infusion — direct human confirmation that flipping the top switch drives the bottom of the chain.^[2]

2. Why it must be pulsed, not run continuously

This is the single most important thing to understand about kisspeptin, and it is where most off-label misuse goes wrong. The GnRH neurons kisspeptin talks to are designed to respond to a rhythm, not a constant tone. In healthy women, a single injection of kisspeptin-54 temporarily increased the number of LH pulses — showing that a bolus nudges the natural pulse generator into action.^[6] But if the signal never turns off, the receptors downstream desensitize and stop responding, and hormone output falls. In other words, continuous kisspeptin does the opposite of what you want. This is the same paradox that governs gonadorelin and the GnRH-agonist drugs used (deliberately, at continuous doses) to shut hormones down in prostate cancer and endometriosis.

3. Direct effects on the sexual and emotional brain

Kisspeptin is not only a hormone trigger. Kisspeptin receptors also sit in limbic regions of the brain involved in emotion, attraction, and arousal. In a placebo-controlled fMRI study of healthy young men, kisspeptin administration enhanced brain activity in response to sexual and couple-bonding images, and improved mood measures — effects that appeared to be central (brain-based) rather than simply a downstream consequence of a testosterone bump.^[5] This dual action — hormones plus brain — is why kisspeptin is studied for low desire and not just for fertility.

What we do NOT know

There is no established long-term human pharmacology for kisspeptin used as a repeated therapy in healthy people: how best to dose it over weeks or months, whether the desensitization risk can be reliably avoided outside a controlled protocol, and what chronic use does over time are all open questions. The mechanisms above are real and human-confirmed for acute (single-session) use — but "we know how it works" is not the same as "we know how to use it safely as an ongoing treatment."

How to read this section: for each area we give the plain-English claim, the mechanism, the population actually studied, the observed effect, and the limitation. What sets kisspeptin apart from most peptides on this site is that several of these findings come from human trials, not just animals — but the trials are small, and none are large Phase 3 efficacy studies.

Raising testosterone and gonadotropins in men

Claim: can raise natural testosterone by stimulating the body's own hormone chain. Mechanism: kisspeptin → GnRH → LH/FSH → testosterone. Population: healthy young men (Phase 1). Effect: an intravenous infusion of kisspeptin-54 significantly increased hormones versus saline — mean LH over 90 minutes was 10.8 vs 4.2 U/L, FSH 3.9 vs 3.2 U/L, and testosterone at 180 minutes 24.9 vs 21.7 nmol/L (all statistically significant).^[2] Limitation: this is a short, acute stimulation in healthy men, not a study of sustained testosterone therapy. The testosterone rise is modest and temporary. There is no trial showing kisspeptin can be used as an ongoing testosterone treatment. The theoretical appeal for men is that, unlike injected testosterone (which suppresses the natural axis and can impair fertility), kisspeptin works through the axis — but "theoretical appeal" is exactly what it remains until longer trials exist.

Triggering egg maturation in IVF (the strongest clinical evidence)

Claim: can mature eggs for IVF egg retrieval with far less risk of a dangerous overstimulation complication. Mechanism: kisspeptin produces a short, more natural LH surge instead of the long, sustained stimulation caused by the standard hCG trigger. Population: women undergoing IVF who were at high risk of ovarian hyperstimulation syndrome (OHSS). Effect: in a Phase 2 dose-finding study of 60 such women, a single subcutaneous dose of kisspeptin-54 (3.2 to 12.8 nmol/kg) matured eggs in about 95% of women, with the highest egg yield at the top dose — and crucially, no woman developed moderate, severe, or critical OHSS.^[3] A follow-up randomized trial in 62 women showed that giving a second dose improved results further: 71% of the double-dose group reached a good egg yield versus 45% with a single dose, without raising OHSS risk.^[4] Limitation: these are specialist fertility-clinic procedures in selected patients, not something an individual replicates at home. But this is genuine, repeated, randomized human efficacy data — the most solid evidence kisspeptin has.

Sexual desire and emotional processing

Claim: may enhance sexual and romantic brain responses and mood. Mechanism: direct action on limbic brain circuits, on top of hormone effects. Population: healthy young men in a placebo-controlled brain-imaging (fMRI) study. Effect: kisspeptin boosted activity in brain regions responding to sexual and couple-bonding images, improved mood, and reduced negative/aversive responses.^[5] Limitation: this measured brain activity and questionnaire responses in a lab, not real-world treatment of a sexual-desire disorder over time. It is a strong proof-of-concept for a central effect on desire, but not proof of a marketable libido treatment. This is why kisspeptin appears in the sexual health goal alongside PT-141.

Restoring hormone pulses in reproductive disorders

Claim: may help conditions where the brain's hormone pulses have gone quiet. Mechanism: kisspeptin can kick-start LH pulsatility. Population: healthy women (mechanism study); the underlying rationale extends to conditions like hypothalamic amenorrhea. Effect: a single kisspeptin-54 injection temporarily increased LH pulse frequency, confirming it engages the natural pulse generator.^[6] Limitation: this is mechanistic evidence in healthy volunteers; kisspeptin is not an established treatment for any specific reproductive disorder.

The honest bottom line on "benefits"

• Kisspeptin has real human trials — a genuine advantage over most research peptides. The IVF trigger data are its most convincing use.^[3][4]
• The trials are small. Sample sizes run from single digits to about 60 subjects. There are no large Phase 3 efficacy trials, and no long-term dosing studies in healthy people.
• Research is concentrated. Most human data come from one group at Imperial College London; independent replication is still limited.
• Acute effects are not the same as a treatment. Raising testosterone for a few hours or lighting up a brain scan is a long way from a proven therapy you can take for months.

Read this first: there is no clinically validated at-home dose for kisspeptin, because it has never been trialed as an ongoing self-administered therapy. The doses below are the actual doses used in published human research studies, described for context and harm reduction — not as a protocol to follow. Kisspeptin is also unusual in that its research doses are given in nmol/kg (weight-based, molar units), not the flat "milligrams" most peptides use, which makes casual dosing especially error-prone.

Doses used in human research (not validated for personal use)

Form	Research dose	Route	Setting studied
Kisspeptin-54	Infusion, e.g. ~4 nmol/kg/hr IV	Intravenous	Phase 1 HPG-axis stimulation in men[2]
Kisspeptin-54	3.2–12.8 nmol/kg, single dose	Subcutaneous	IVF oocyte-maturation trigger[3]
Kisspeptin-54	Second dose ~10 hr after the first	Subcutaneous	Improved IVF egg yield[4]
Kisspeptin-54	Single SC bolus	Subcutaneous	LH-pulsatility study in women[6]
Kisspeptin-10	Lower, short-acting	IV / SC	Acute stimulation studies (shorter half-life)

Why the two forms differ: kisspeptin-54 lasts longer in the body and is what the major clinical trials used. Kisspeptin-10 is shorter-acting, which makes it useful for brief acute tests but means it clears quickly. Neither has an established repeat-dosing schedule for healthy adults.

The one rule that matters most: pulse it, never run it continuously

Because continuous exposure desensitizes the system and suppresses hormones, every human protocol uses a single bolus, spaced boluses, or a short infusion — not a steady, ongoing dose.^[6] Anyone using kisspeptin off-label who doses it too frequently will drive it toward the continuous pattern that lowers hormones. Spacing and restraint, not frequency, are the point.

Reconstitution math, with a worked example

Research-grade kisspeptin ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The volume formula is the same as any peptide:

Concentration (mcg/mL) = vial amount (mcg) ÷ water added (mL)

Worked example: take a 5 mg (5,000 mcg) vial and add 2 mL of bacteriostatic water. That gives 5,000 ÷ 2 = 2,500 mcg/mL. To draw a hypothetical 500 mcg amount: 500 ÷ 2,500 = 0.20 mL, which is 20 units on a standard 100-unit insulin syringe.

Important honesty note: kisspeptin's real research doses are weight-based in nmol/kg, and converting those into a flat mcg volume requires the exact molecular weight of the specific form (kisspeptin-54 and kisspeptin-10 differ substantially). The example above shows the mechanics of reconstitution only — it is not a recommended dose. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a step-by-step walkthrough. If the nmol/kg math is unfamiliar to you, that is a signal this compound is not a good beginner project.

Preparation and storage

• Reconstitute gently: wipe the stopper with alcohol, inject the water slowly down the vial wall, and swirl (do not shake) until dissolved. Label with date and concentration.
• Lyophilized powder: store frozen (around -20°C) for long-term storage, protected from light.
• Reconstituted solution: refrigerate at 2–8°C, protect from light, and use promptly — clinical preparations are typically used within about 24 hours. Never freeze-thaw repeatedly, and discard anything cloudy or discolored.

See the full peptide storage guide. None of the above is a recommendation to self-administer an unapproved compound — it describes how the research doses are structured.

Straight talk: across the published trials — healthy men and women, and IVF patients — kisspeptin has shown a favorable acute safety profile, with no serious drug-related adverse events reported and its most notable feature being a safety advantage (near-absence of OHSS in IVF).^[3] But the trials are small (totaling in the hundreds, not thousands, of subjects) and short. Long-term, repeated dosing in healthy adults has not been studied, so "well tolerated in trials" is reassurance, not a guarantee of safety for off-label use.

Reported side effects

Effect	Frequency	Notes
Injection-site reactions	Common, mild	Transient redness or soreness; self-resolving
Transient flushing	Occasional	Vasomotor; typically resolves within minutes
Mild headache	Occasional	Usually early doses
Rise in LH / FSH / testosterone / estradiol	Expected	The intended pharmacological action, not an adverse effect per se
Loss of effect with over-frequent dosing (tachyphylaxis)	Possible	Continuous/near-continuous exposure desensitizes downstream neurons
Moderate/severe OHSS when used as an IVF trigger	Very rare / not seen	Zero cases across the Phase 2 cohorts — a defining advantage over hCG[3]
Serious drug-related adverse events	None reported in published trials	Sample sizes remain small

The OHSS advantage in IVF, explained

The most clinically meaningful safety finding is about IVF. To mature eggs before retrieval, clinics normally give an hCG "trigger." hCG has a long half-life and produces sustained LH-like activity, which can overstimulate the ovaries and cause ovarian hyperstimulation syndrome (OHSS) — fluid shifts, painful ovarian enlargement, blood-clot risk, and in rare cases death. Kisspeptin instead produces a short, self-limiting LH surge that mimics the natural cycle. In the Phase 2 trials, no woman given a kisspeptin trigger developed moderate, severe, or critical OHSS.^[3][4] This is the clearest example of kisspeptin being not just effective but genuinely safer than the current standard for a specific job.

The pulsatile-vs-continuous paradox (a safety issue, not just an efficacy one)

As covered in the mechanism section, continuous kisspeptin exposure desensitizes GnRH neurons and ultimately suppresses LH/FSH and downstream hormones. For anyone using kisspeptin off-label, dosing too often is the fastest way to turn an intended stimulant into a suppressant. If effects fade over a protocol, the fix is usually less frequent dosing, not more.

Who should not use it, and interactions

• Hormone-sensitive cancers (breast, prostate, endometrial, ovarian): kisspeptin raises downstream sex hormones, which can feed hormone-responsive tumors. Avoid outside oncology-supervised research.
• Precocious puberty: contraindicated — kisspeptin drives the puberty-initiating signal.
• Pregnancy and breastfeeding: effects are unknown; avoid.
• Pituitary tumors, especially gonadotropin-secreting adenomas: could worsen.
• Known hypersensitivity to kisspeptin or formulation excipients.
• People on hormonal therapy (testosterone replacement, birth-control pills, GnRH agonists/antagonists, aromatase inhibitors): effects become unpredictable when combined with other axis-modulating drugs. GnRH agonists (leuprolide, goserelin) share the same desensitization pitfall; GnRH antagonists (cetrorelix, ganirelix) block the downstream pathway and cancel the effect; exogenous testosterone or estrogen blunts the LH/FSH rise through negative feedback. Involve an endocrinologist or reproductive specialist before combining anything.

What to do if you experience side effects

• Injection-site reactions: rotate sites; typically resolve within a day or two.
• Flushing or headache: usually transient; hydrate and rest.
• Fading effect: suspect too-frequent dosing (tachyphylaxis) and reduce frequency.
• Signs of OHSS after an IVF trigger (abdominal distension, severe pain, reduced urination, shortness of breath): escalate to fertility-clinic care immediately. It is far less likely with kisspeptin than hCG, but not impossible.
• Allergic reaction: discontinue and seek emergency care.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: kisspeptin sold outside a clinical trial is an unregulated research compound, so purity and identity vary widely between suppliers. There is an added wrinkle here: "kisspeptin" can mean the full-length kisspeptin-54 (used in the trials) or the shorter kisspeptin-10, and they are not interchangeable in dose or duration. Knowing exactly which form and what purity you have is the single most useful skill.

What a credible product should show

• Third-party Certificate of Analysis (COA): independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the specific form (kisspeptin-54 vs kisspeptin-10 have very different weights).
• Explicit form labeling: the product should clearly state whether it is kisspeptin-54 or kisspeptin-10 — vague "kisspeptin" with no form is a red flag.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• No stated form (54 vs 10) or molecular weight
• Pre-mixed "ready to use" liquid (shorter shelf life, contamination risk)
• Prices far below the market
• Explicit human-use, fertility, or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any indication, in any country.
• Investigational in the US: legitimate human use occurs inside clinical trials and research protocols. Kisspeptin's status for pharmacy compounding is unsettled and should not be assumed to be permitted; treat any therapeutic availability claim with skepticism.
• Not a controlled substance: kisspeptin is not DEA-scheduled.
• Research-market product is unregulated: quality is the buyer's responsibility, and no third party guarantees identity, purity, or sterility.

For the complete legal picture, read Are Peptides Legal?

Kisspeptin is easiest to understand by contrasting it with the peptides it is most often confused with. None of these comparisons are backed by head-to-head trials — they contrast where each molecule acts and what the evidence shows.

Kisspeptin vs. Gonadorelin (GnRH)

Factor	Kisspeptin	Gonadorelin
Where it acts	Top of the chain — on GnRH neurons in the brain	One step lower — directly on the pituitary
Signal it sends	Tells the brain to release its own GnRH	Acts as GnRH itself
Must be pulsed?	Yes — continuous exposure suppresses hormones	Yes — same paradox
Approval	Not FDA-approved (investigational)	Has approved diagnostic history; used off-label for axis support

In short, kisspeptin works one rung higher than gonadorelin. Both depend on pulsatile dosing, and both aim to keep the natural axis running rather than replacing hormones from outside.

Kisspeptin vs. PT-141 (desire)

PT-141 (bremelanotide) is a melanocortin-system peptide that acts on brain pathways for sexual arousal and is FDA-approved for premenopausal women with low desire. Kisspeptin also affects the sexual brain,^[5] but additionally drives the reproductive hormone axis, and it is not approved for anything. They overlap on "desire" but sit in different systems and have very different regulatory status — see the sexual health goal for how these fit together.